Showing results (231-240 of 322) with videos related to
Sort By:
Pageof 33
Blood|November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelHartmut Döhner, Elihu Estey, David Grimwade, et al.Nature|July 2, 2015
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDSJan Krönke, Emma C Fink, Paul W Hollenbach, et al.Cancer Cell|December 11, 2007
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate allelesStefan Fröhling, Claudia Scholl, Ross L Levine, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2022
Clonal Hematopoiesis and Risk of Incident Lung CancerRuiyi Tian, Brian Wiley, Jie Liu, et al.Blood|July 7, 2022
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNHartmut Döhner, Andrew H Wei, Frederick R Appelbaum, et al.Blood|May 3, 2019
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogsAdam S Sperling, Michael Burgess, Hasmik Keshishian, et al.Blood|May 8, 2009
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesOmar Abdel-Wahab, Ann Mullally, Cyrus Hedvat, et al.Blood Cancer Discovery|May 24, 2021
Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignanciesAline Renneville, Jessica A Gasser, Daniel E Grinshpun, et al.Blood|August 12, 2024
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendationsHartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, et al.JCI Insight|December 22, 2020
Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AMLZuzana Tothova, Anne-Laure Valton, Rebecca A Gorelov, et al.Pageof 33